Innovative Insulin Injection Sites Map to Minimize Lipohypertrophy Risk
NCT07561086 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 170
Last updated 2026-05-07
Summary
Background:
Patients on long-term insulin therapy frequently develop a condition called lipohypertrophy (LH), which involves the accumulation of abnormal fatty tissue at insulin injection sites. This condition is caused by repeated injections in the same area and can lead to inconsistent insulin absorption, unpredictable blood sugar levels, and increased risks of hypoglycemia and hyperglycemia. While standard care often includes verbal instructions on site rotation, many patients continue to struggle with technique and develop these complications.
Study Purpose:
This study aims to evaluate the effectiveness of a novel "Insulin Injection Sites Map" (provided in either digital or physical format) compared to standard verbal care. The study seeks to determine if this structured, visual mapping tool helps patients better manage their injection rotation, reduces the occurrence and severity of lipohypertrophy, and ultimately improves glycemic control (as measured by HbA1c and fasting blood glucose).
Study Design:
This is a prospective, randomized controlled trial (RCT) conducted at the outpatient medical clinic of Matrouh General Hospital. The study includes adult participants (aged 18 and older) diagnosed with Type 1 or Type 2 diabetes who have been using insulin therapy for at least six months.
Participants are divided into two groups:
Intervention Group: Patients who receive the novel structured insulin injection sites map and instructions on systematic rotation.
Control Group: Patients who receive routine care, consisting of standard verbal instructions on site rotation without visual mapping aids.
Outcome Measures:
Over a six-month follow-up period, the study monitors and compares both groups on the following key metrics:
Incidence and Severity of Lipohypertrophy: Evaluated through physical inspection and palpation of injection sites for lumps, firmness, or tenderness.
Adherence to Rotation Protocols: Measured using patient logs and site rotation scores to determine if participants are following the recommended rotation sequence.
Glycemic Control: Tracked through clinical monitoring of HbA1c percentages and fasting blood glucose levels to assess the impact of better injection technique on overall diabetes management.
Conditions
- Type 1 Diabetes Mellitus
- Lipohypertrophy
Interventions
- BEHAVIORAL
-
Insulin Injection Site Mapping Tool
Participants receive an evidence-based insulin injection site mapping tool designed to guide systematic rotation of insulin injection sites and reduce the risk of insulin-induced lipohypertrophy. The intervention is supported by structured education and follow-up reinforcement.
Sponsors & Collaborators
-
Helwan University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-01
- Primary Completion
- 2026-01-30
- Completion
- 2026-01-30
Countries
- Egypt
Study Locations
More Related Trials
-
Avoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics
NCT06782568 ·Status: RECRUITING ·Phase: NA
-
Lypo-hypertrofia Characterization in Diabetes
NCT02278926 ·Status: COMPLETED
-
Lipohypertrophy Monitoring Study
NCT04659330 ·Status: COMPLETED ·Phase: NA
-
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
NCT01505673 ·Status: COMPLETED ·Phase: PHASE4
-
Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique
NCT03229850 ·Status: WITHDRAWN ·Phase: NA
-
A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity
NCT07578584 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
NCT02777073 ·Status: COMPLETED ·Phase: NA
-
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
NCT02324842 ·Status: COMPLETED ·Phase: NA
-
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
NCT01607450 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
GLP-1 Receptor Expression in CHI
NCT03768518 ·Status: UNKNOWN
-
Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes
NCT02617654 ·Status: COMPLETED ·Phase: PHASE2
-
HbA1c Variability in Type II Diabetes
NCT02879409 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Metabolomic Analysis of Hepatic Insulin Resistance
NCT01833403 ·Status: COMPLETED ·Phase: NA
-
Liraglutide in Type 1 Diabetes
NCT01612468 ·Status: COMPLETED ·Phase: PHASE4
-
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
NCT04387201 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function
NCT01790308 ·Status: UNKNOWN ·Phase: PHASE4
-
Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia
NCT02337660 ·Status: COMPLETED ·Phase: NA
-
Regulation of Tissue Lipolysis by Insulin in Type 2 Diabetes
NCT01680133 ·Status: COMPLETED
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
NCT06976619 ·Status: RECRUITING ·Phase: PHASE2
-
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
NCT03582956 ·Status: TERMINATED ·Phase: NA
-
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
NCT06333496 ·Status: COMPLETED ·Phase: NA
-
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
NCT02765399 ·Status: COMPLETED ·Phase: PHASE4
-
Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes
NCT02016846 ·Status: UNKNOWN ·Phase: PHASE3
-
Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 with Non-alcoholic Hepatic Steatosis
NCT04270656 ·Status: COMPLETED ·Phase: NA
-
Leptin to Treat Severe Insulin Resistance - Pilot Study
NCT00027456 ·Status: COMPLETED ·Phase: PHASE2